ENew York-Kwiveki ephelileyo, i-US Food and Drug Administration inike ugunyaziso losetyenziso olungxamisekileyo kwi-Siemens Healthineers kwi-Advia Centaur SARS-CoV-2 IgG okanye uvavanyo lwe-sCOVG.
I-Chemiluminescence immunoassay yenzelwe ukufunyaniswa komgangatho kunye nesiqingatha sobungakanani be-immunoglobulin G okanye i-IgG ngokuchasene ne-SARS-CoV-2 kwiserum kunye neplasma.Uvavanyo luqhutywa kwi-Siemens 'Advia Centaur XP, Advia Centaur XPT kunye ne-Advia Centaur CP immunoassay systems.
Ngokutsho kwe-FDA, olu vavanyo lunokusetyenziswa yiyo nayiphi na ilebhu evunyiweyo ye-CLIA ukwenza uvavanyo oluphakathi okanye oluntsonkothileyo kakhulu.
NgoMatshi walo nyaka, i-SARS-CoV-2 IgG immunoassay eqhutywa ngu-Siemens, ekomkhulu e-Erlangen, eJamani, kuhlalutyi lwayo lwe-Atellica IM, iphumelele i-EUA ye-FDA.
Umthetho wabucala.Imimmiselo nemiqathango.Ilungelo lokushicilela © 2021 GenomeWeb, iyunithi yoshishino yeCrain Communications.onke Amalungelo Agciniwe.
Ixesha lokuposa: Jul-21-2021